Company intelligence / Profile preview

Sequantrix

Aachen, North Rhine-Westphalia, Germany

Ownership: Private
Development stage: Other

Overview

Sequantrix is a pre-clinical biotech spin-out from Uniklinik RWTH Aachen developing novel antifibrotic drugs; it leverages some of the world’s largest human multi‑modal single‑cell datasets in fibrotic diseases to discover and validate new targets and aims to advance anti-fibrotic drug candidates to clinical proof of concept.[1][2][3][4][5] Public information to date focuses on target discovery and partnerships (e.g., Chugai) rather than specific clinical results, indicating programs are still pre‑clinical.[2][4][5][6]

Therapeutic areas: ImmunologyRare Diseases
Industry: Biotech

Partnerships

Chugai Pharmaceutical – agreement to use Sequantrix’s AI and single-cell–based discovery platform (announced April 2025)

Beyond the preview

Go deeper on Sequantrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequantrix.

Explore the full profile